Biotinylated Human IL-17F Protein, His,Avitag? (MALS verified)
分子別名（Synonym）
IL-17F, Interleukin-17F, Cytokine ML-1
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human IL-17F, His,Avitag (ILF-H82Q9) is expressed from human 293 cells (HEK293). It contains AA Arg 31 - Gln 163 (Accession # Q96PD4-1).
Predicted N-terminus: His
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 18.5 kDa. The protein migrates as 25-28 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
白細(xì)胞介素17F（IL-17F）亦稱白細(xì)胞介素24（IL-24）、細(xì)胞因子ML-1，是一種分泌型二硫鍵連接的同源二聚體，屬于IL-17家族成員。人類和小鼠的IL-17家族至少包含六個(gè)成員：IL-17A、IL-17B、IL-17C、IL-17D、IL-17E（又稱IL-25）及IL-17F（又稱IL-24）。該家族是由結(jié)構(gòu)相關(guān)細(xì)胞因子組成的蛋白群體，它們共同具有高度保守的C端區(qū)域，但N端區(qū)域及其獨(dú)特生物學(xué)功能各不相同。IL-17F/IL-24在活化的CD4+T細(xì)胞及活化單核細(xì)胞中表達(dá)（靜息態(tài)細(xì)胞不表達(dá)），能刺激IL-6、IL-8和粒細(xì)胞集落刺激因子等其他細(xì)胞因子的產(chǎn)生，并可調(diào)節(jié)軟骨基質(zhì)代謝。IL-17F/IL-24能促進(jìn)外周血單個(gè)核細(xì)胞（PBMC）與T細(xì)胞增殖，同時(shí)具有抑制血管生成的作用。IL-17F的缺陷是導(dǎo)致6型家族性念珠菌病（CANDF6）的致病原因。
關(guān)鍵字： IL-17F;IL-17F蛋白;IL-17F重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。